Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 01:29:01 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad
Next:This Week: Home sales, Fed meeting minutes and consumer sentiment index
You may also like
- Shooting injures 2 at Missouri high school graduation ceremony
- Stop prescribing puberty blockers to children
- Moment Iran began its 300
- Silk culture festival and temple fair parade held in Huzhou
- Nadal returns to Roland Garros to practice amid doubts over fitness and form
- New Godzilla x Kong film continues to lead China box office
- Pelicans wing Brandon Ingram returns from a knee injury in regular
- Wayne Rooney reveals why he isn't appearing on Match of the Day as planned this weekend... as the ex
- Padres second baseman Xander Bogaerts leaves game against Braves with shoulder injury